Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · Real-Time Price · USD
6.75
+0.19 (2.90%)
At close: May 12, 2025, 4:00 PM
6.77
+0.02 (0.30%)
After-hours: May 12, 2025, 5:42 PM EDT
Sage Therapeutics Revenue
Sage Therapeutics had revenue of $14.06M in the quarter ending March 31, 2025, with 77.97% growth. This brings the company's revenue in the last twelve months to $47.40M, down -47.94% year-over-year. In the year 2024, Sage Therapeutics had annual revenue of $41.24M, down -52.30%.
Revenue (ttm)
$47.40M
Revenue Growth
-47.94%
P/S Ratio
8.71
Revenue / Employee
$134,289
Employees
353
Market Cap
422.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.24M | -45.21M | -52.30% |
| Dec 31, 2023 | 86.46M | 78.77M | 1,024.84% |
| Dec 31, 2022 | 7.69M | 1.38M | 21.85% |
| Dec 31, 2021 | 6.31M | -1.11B | -99.43% |
| Dec 31, 2020 | 1.11B | 1.11B | 16,123.06% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
SAGE News
- 1 day ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation - Accesswire
- 4 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation - Accesswire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - Accesswire
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 11 days ago - Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 13 days ago - Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates - Business Wire
- 13 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation - Accesswire